Zevra Therapeutics, Inc. (NASDAQ:ZVRA) reported its second-quarter financial results Tuesday. Here’s a look at the details from the report. The Details: Zevra Therapeutics reported quarterly losses of 48 cents per share, which missed the analyst consensus estimate by 9.09%. Quarterly sales came in at $4.449 million, which beat the analyst consensus estimate of $4.412 million. The components of revenue during the second quarter included $3.1 million in net reimbursements from the French EAP for arimoclomol, $1.3 million of royalties and other reimbursements under the AZSTARYS License Agreement,…